Inclusion Criteria:
  1. age older than 60 years;
  2. moderate to severe or severe mitral regurgitation;
  3. symptoms (New York Heart Association [NYHA] cardiac function class â‰¥2) related to MR;
  4. the primary regurgitant jet originated from malcoaptation of the A2 and P2 scallops of the mitral valve;
  5. high risk for surgery according the MVARC criteria;
  6. providing signed informed consent.
Exclusion Criteria:
  1. acute myocardial infarction in the prior 4 weeks of the intended treatment;
  2. any interventional or surgical cardiac procedure performed within 30 days prior;
  3. the need for any other cardiac surgery;
  4. echocardiographic evidence of intracardiac mass, thrombus, or vegetation;
  5. life expectancy within 12 months;
  6. moderate or severe aortic stenosis or regurgitation;
  7. mitral valve orifice area <3.5 cm2;
  8. untreated significant coronary stenosis;
  9. history of mitral valvuloplasty;
 10. Infective endocarditis and rheumatic heart disease;
 11. untreated cardiogenic shock, acute pulmonary congestion;
 12. unfavored mitral valve anatomy that may preclude device implantation including:
     calcification or significant cleft in area of the A2 and/or P2 scallops, significant regurgitation beyond A2 or P2 scallops and short posterior leaflet (<10mm).
 13. Other clinical trials that the subjects participated in have not reached the end point.